Regeneron wins appeals court orders backing halt on Eylea biosimilars

Two biotech companies failed to reverse orders barring them from selling biosimilars of Regeneron’s eye disease drug Eylea in rulings from a federal appeals court. The US Court of Appeals for the Federal Circuit affirmed ...